Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Almirall begins phase III Sativex cancer pain studies

Almirall begins phase III Sativex cancer pain studies

2nd December 2010

Almirall has launched a new clinical development programme to evaluate the efficacy and safety of Sativex for cancer pain treatment.

The company said it will conduct two phase III trials of the drug, which is designed to treat advanced cancer patients who experience inadequate analgesia during chronic pain optimised with opioids.

Each trial will be randomised and placebo-controlled, featuring approximately 370 patients in Europe, North America, Latin America and Asia.

The phase III programme, which will also include the extension of a long-term study, is now underway at GW Pharmaceuticals.

Almirall said the first patient for the first study will be recruited this month, with the second trial due to begin in mid-2011.

Sativex is already licensed for the treatment of spasticity in people with multiple sclerosis in Europe.

In October, the company presented clinical data from three phase III trials supporting the drug's efficacy in this area at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis.ADNFCR-8000103-ID-800268122-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.